Literature DB >> 32409870

Low metabolic activity in primary gastric adenocarcinoma is associated with resistance to chemoradiation and the presence of signet ring cells.

Kazuto Harada1,2, Madhavi Patnana3, Xuemei Wang4, Masaaki Iwatsuki1,2, Mariela A Blum Murphy1, Meina Zhao1, Prajnan Das5, Bruce D Minsky5, Brian Weston6, Jeffrey H Lee6, Manoop S Bhutani6, Jeannelyn S Estrella7, Namita Shanbhag1, Naruhiko Ikoma8, Brian D Badgwell8, Jaffer A Ajani9.   

Abstract

PURPOSES: Preoperative chemoradiation is a potential treatment option for localized gastric adenocarcinoma (GAC). Currently, the response to chemoradiation cannot be predicted. We analyzed the pretreatment maximum standardized uptake value (SUVmax) and total lesion glycolysis (TLG) on positron emission tomography/computed tomography as potential predictors of the response to chemoradiation.
METHODS: We analyzed the SUVmax and TLG data from 59 GAC patients who received preoperative chemoradiation. We used logistic regression models to predict a pathologic complete response (pCR) and Kaplan-Meier curves to determine overall survival among patients with high and low SUVmax or TLG.
RESULTS: Twenty-nine patients (49%) had Siewert type III adenocarcinoma and 30 (51%) had tumors located in the lower stomach. Forty-one patients had poorly differentiated GAC, and 26 had signet ring cells. The median SUVmax was 7.3 (0-28.2) and the median TLG was 56.6 (0-1881.5). Patients with signet ring cells had a low pCR rate, as well as a low SUVmax and TLG. In the multivariable logistic regression model, high SUVmax was a predictor of pCR (odds ratio = 11.1, 95% confidence interval = 2.12-50.0, p = 0.004). Overall survival was not associated with the SUVmax (log-rank p = 0.69) or TLG (log-rank p = 0.85)
CONCLUSION: A high SUVmax was associated with sensitivity to chemoradiation and pCR in GAC, and signet ring cells seemed to confer resistance.

Entities:  

Keywords:  Chemoradiation; Gastric adenocarcinoma; Positron emission tomography (PET); Total lesion glycolysis (TLG)

Mesh:

Year:  2020        PMID: 32409870      PMCID: PMC9396945          DOI: 10.1007/s00595-020-02018-2

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.540


  34 in total

1.  Reporting recommendations for tumor marker prognostic studies.

Authors:  Lisa M McShane; Douglas G Altman; Willi Sauerbrei; Sheila E Taube; Massimo Gion; Gary M Clark
Journal:  J Clin Oncol       Date:  2005-09-19       Impact factor: 44.544

2.  Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome.

Authors:  J A Ajani; P F Mansfield; C H Crane; T T Wu; S Lunagomez; P M Lynch; N Janjan; B Feig; J Faust; J C Yao; R Nivers; J Morris; P W Pisters
Journal:  J Clin Oncol       Date:  2005-02-20       Impact factor: 44.544

3.  The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging.

Authors:  Mahul B Amin; Frederick L Greene; Stephen B Edge; Carolyn C Compton; Jeffrey E Gershenwald; Robert K Brookland; Laura Meyer; Donna M Gress; David R Byrd; David P Winchester
Journal:  CA Cancer J Clin       Date:  2017-01-17       Impact factor: 508.702

4.  Preoperative chemo-radiation-induced ulceration in patients with esophageal cancer: a confounding factor in tumor response assessment in integrated computed tomographic-positron emission tomographic imaging.

Authors:  Jeremy J Erasmus; Reginald F Munden; Mylene T Truong; Jeremy J Ho; Wayne L Hofstetter; Homer A Macapinlac; Arlene M Correa; Tsung-Teh Wu; John F Bruzzi; Edith M Marom; Bradley S Sabloff; Jaffer A Ajani; Ritsuko Komaki; Zhongxing Liao; Jeffrey H Lee; Norio Fukami; Robert Bresalier; Stephen G Swisher
Journal:  J Thorac Oncol       Date:  2006-06       Impact factor: 15.609

5.  Variable 18F-fluorodeoxyglucose uptake in gastric cancer is associated with different levels of GLUT-1 expression.

Authors:  Hakan Alakus; Mert Batur; Matthias Schmidt; Uta Drebber; Stephan E Baldus; Daniel Vallböhmer; Klaus L Prenzel; Ralf Metzger; Elfriede Bollschweiler; Arnulf H Hölscher; Stefan P Mönig
Journal:  Nucl Med Commun       Date:  2010-06       Impact factor: 1.690

6.  Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging. The Visual Response Score and the Change in Total Lesion Glycolysis.

Authors:  Steven M. Larson; Yusuf Erdi; Timothy Akhurst; Madhu Mazumdar; Homer A. Macapinlac; Ronald D. Finn; Cecille Casilla; Melissa Fazzari; Neil Srivastava; Henry W.D. Yeung; John L. Humm; Jose Guillem; Robert Downey; Martin Karpeh; Alfred E. Cohen; Robert Ginsberg
Journal:  Clin Positron Imaging       Date:  1999-05

7.  FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings.

Authors:  Alexander Stahl; Katja Ott; Wolfgang Andreas Weber; Karen Becker; Thomas Link; Jörg-Rüdiger Siewert; Markus Schwaiger; Ulrich Fink
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-11-08       Impact factor: 9.236

8.  The Proportion of Signet Ring Cell Component in Patients with Localized Gastric Adenocarcinoma Correlates with the Degree of Response to Pre-Operative Chemoradiation.

Authors:  Nikolaos Charalampakis; Graciela M Nogueras González; Elena Elimova; Roopma Wadhwa; Hironori Shiozaki; Yusuke Shimodaira; Mariela A Blum; Jane E Rogers; Kazuto Harada; Aurelio Matamoros; Tara Sagebiel; Prajnan Das; Bruce D Minsky; Jeffrey H Lee; Brian Weston; Manoop S Bhutani; Jeannelyn S Estrella; Brian D Badgwell; Jaffer A Ajani
Journal:  Oncology       Date:  2016-04-06       Impact factor: 2.935

Review 9.  Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance.

Authors:  Micol Eleonora Fiori; Simone Di Franco; Lidia Villanova; Paola Bianca; Giorgio Stassi; Ruggero De Maria
Journal:  Mol Cancer       Date:  2019-03-30       Impact factor: 27.401

10.  Patterns of relapse in patients with localized gastric adenocarcinoma who had surgery with or without adjunctive therapy: costs and effectiveness of surveillance.

Authors:  Elena Elimova; Rebecca S Slack; Hsiang-Chun Chen; Venkatram Planjery; Hironori Shiozaki; Yusuke Shimodaira; Nick Charalampakis; Quan Lin; Kazuto Harada; Roopma Wadhwa; Jeannelyn S Estrella; Dilsa Mizrak Kaya; Tara Sagebiel; Jeffrey H Lee; Brian Weston; Manoop Bhutani; Mariela Blum Murphy; Aurelio Matamoros; Bruce Minsky; Prajnan Das; Paul F Mansfield; Brian D Badgwell; Jaffer A Ajani
Journal:  Oncotarget       Date:  2017-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.